A new trademark application for COVID-KUSH was filed with the U.S. Patent and Trademark Office (USPTO), on July 30, 2020. The applicant is Anthony Ariza dba Covid-Kush of Santa Clara, California. The identification of goods and services indicates it is a mark for use in International Class 30, for gelatin-based chewy candies; flavored, sweetened gelatin …
U.S. Patent No. 10,695,361 B2
Given the current coronavirus pandemic, much has been discussed about possible vaccine trials and antiviral treatments to coronavirus. One patent directed to therapeutic use is U.S. Patent No. 10,695,361 B2 (‘361) issued on June 30, 2020, entitled ”Methods for Treating Arenaviridae and Coronaviridae Virus Infections.” It was issued to inventors Michael O’Neil Hanrahan Clarke, Joy …
Method of Preparation Claims Patent-Eligible in Illumina Modified Opinion
On August 3, 2020, the Court of Appeals for the Federal Circuit issued a modified opinion in Illumina, Inc. v. Ariosa Diagnostics, Inc.,[1] reiterating its earlier opinion[2] finding claims directed to method of preparing cell-free fetal DNA in maternal blood as patent-eligible subject matter under 35 U.S.C. §101. This modified opinion reflected Ariosa’s recent petition …
American Axle Denied en banc Review
On July 31, 2020, the Court of Appeals for the Federal Circuit denied American Axle’s petition for en banc review, in American Axle & Manuf., Inc. v. Neapco Holdings LLC,[1] with those judges seeking review not able to muster a majority of the entire panel. This is the second iteration[2] of appellate review for American …
U.S. Patent No. 10,512,629 B1
U.S. Patent No. 10,512,629 B1 (‘629) issued on December 24, 2019, entitled ”Compositions Comprising a Cannabinoid and Spilanthol.” It was issued to inventor Zohar Koren of Gan Ner, Israel. The applicant/assignee is SciCann Therapeutics, Inc., of Toronto, Canada. The specification discloses fixed-dose combination (FDC) therapeutic compound of one cannabinoid and spilanthol for treatment of various …
SCOTUS Watch: SCOTUS Finds Adding “.com” to “Booking” Makes it a Non-Generic Registrable Mark
In a major ruling, the U.S. Supreme Court held in U.S.P.T.O. v. Booking.com B.V.,[1] that an otherwise generic mark used in commerce conveys source-identifying characteristics when used with the “.com” top-level domain (TLD). In her majority opinion, Justice Ginsburg opined that since only one domain name owner can hold one particular domain name at any …
U.S. Patent No. 10,485,373 B1
U.S. Patent No. 10,485,373 B1 (‘373) issued on November 26, 2019, entitled ”Method for Cannabinoid Delivery Into Beverages.” It was issued to inventors Rory Chesley Patrick Millikin of Kelowna, Canada, and Matthew Kennedy of Westminster, California. The assignee is Drive Foods Corporation of Westminster, California. The specification discloses a new cannabinoid beverage delivery system. According …
U.S. Patent No. 10,485,771 B2
U.S. Patent No. 10,485,771 B2 (‘771) issued on November 26, 2019, entitled ”Methods of Regulating Cannabinoid Receptor Activity-Related Disorders and Diseases.” It was issued to inventors Irving W. Wainer of Washington, DC, Michel Bernier of Pikesville, Maryland, and Rajib K. Paul of Baltimore, Maryland. The applicant/assignee is the U.S. Department of Health & Human Services, …
U.S. Patent No. 10,477,791 B2
U.S. Patent No. 10,477,791 B2 (‘791) issued on November 19, 2019, entitled ”Method of Production of Phytocannabinoids for Use in Medical Treatments.” It was issued to inventor Peter Andrew Whitton of Leicester, Great Britain. The applicant/assignee is Cell Science Holding Ltd. of Limassol, Cyprus. The specification discloses a new process for producing phytocannabinoids, or the …
U.S. Patent No. 10,456,435 B2
U.S. Patent No. 10,456,435 B2 (‘435) issued on October 29, 2019, entitled ”Topical Antiviral Formulations and Methods of Using the Same.” It was issued to applicant/inventor Christopher A. McElvany of Denver, Colorado. The specification discloses an antiviral composition for treatment of herpes simplex virus (HSV), or the common cold sore. The sole claim in the …